Meeting
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
Authors
Shiqi Li
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China
Shiqi Li , Zhi Yang , Lin Liu , Zhongtao Yuan , Yingzi Zhang , Le Luo , Lihua Zhang , Yingnian Chen , Qianzhen Zhang , Junjie Shen , Yunyan Li , Linling Wang , Meiling Wang , Wei Zhu , Yufeng Huang , Youcheng Wang , Yancheng Dong , Sanbin Wang , Cheng Qian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT04271410
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7553)
DOI
10.1200/JCO.2023.41.16_suppl.7553
Abstract #
7553
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2024 ASCO Annual Meeting
Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.
First Author: Armin Ghobadi
Poster
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
First Author: Boyu Hu